Fotopoulos Alexandros 4
4 · Passage BIO, Inc. · Filed Jun 20, 2023
Insider Transaction Report
Form 4
Fotopoulos Alexandros
Chief Technical Officer
Transactions
- Exercise/Conversion
Common Stock
2023-06-15+12,500→ 32,745 total - Sale
Common Stock
2023-06-16$0.93/sh−4,052$3,778→ 28,693 total - Exercise/Conversion
Restricted Stock Units
2023-06-15−12,500→ 25,000 total→ Common Stock (12,500 underlying)
Footnotes (4)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- [F3]1/4 of the RSUs vested on June 15, 2022, and the remainder vested or vests as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- [F4]These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.